日本2022版食管癌诊治指南在中国的接受度——中国红杉树专家调研

Acceptance of Japanese esophageal cancer practice guidelines 2022 in China:a survey by Chinese redwood experts

日本的食管癌临床研究质量非常高,其食管癌诊治指南在国际上独树一帜。近年来,中国食管癌临床研究已经进入了新的发展阶段,目前进行中的临床研究数量居于世界前列。中国部分食管外科专家就日本指南中的外科相关临床问题进行了讨论和审视,并针对诊治实践中能否接受相关推荐进行投票,希望本次投票结果的介绍能够给中国胸外科同道提供借鉴意义。

The quality of clinical trials on esophageal cancer in Japan is very high,and its practice guidelines are unique in the world.In recent years,the clinical research of esophageal cancer in China has entered a new stage of development,and the number of clinical trials ranks among the top in the world.Some esophageal surgery experts in China discussed and reviewed the clinical issues related to surgery in the Japanese guidelines and voted on whether the relevant recommendations could be accepted in China.It is hoped that the introduction of the voting results can provide a reference for Chinese thoracic surgery colleagues.